Cardinal Health Was Supposed to Beat UnitedHealth. Did It? Will It?

UnitedHealth returned 35.2% over the past 12 months and added 27.0% in the last month, with Q1 2026 adjusted EPS of $7.23 beating the $6.61 consensus and full-year EPS guidance raised above $18.25. Cardinal Health lagged on recent momentum, down 10.7% in the past month, despite a Q3 FY26 EPS beat of $3.17 versus $2.79; its revenue miss, operating income decline, and goodwill impairment pressured results. The article’s forward view favors Cardinal Health on 24.0% implied upside from the 24/7 target and faster FY26 EPS growth guidance, while UnitedHealth still faces DOJ and Medicare Advantage overhangs.

Analysis

This is a classic quality-vs-turnaround regime split, but the second-order edge is that the market is now paying for proof in UNH and paying for optionality in CAH. UNH’s de-risking has already re-rated the name toward “normalized compounder,” which usually compresses forward multiple expansion unless earnings surprise keeps accelerating; that makes near-term upside more dependent on execution staying flawless than on continued sentiment recovery. CAH, by contrast, has a more asymmetrical setup because the market is discounting a recent operational hiccup while still rewarding the combination of guidance inflection and lower beta.

The important nuance is that UNH’s strength can become a source of fragility. Once a turnaround stock moves from “recovery” to “consensus winner,” incremental buyers become less price-insensitive, and any regulatory headline or medical-cost wobble can trigger a fast de-grossing because expectations are now much higher. In health care, the biggest drawdowns often happen not when fundamentals are worst, but when fundamentals are merely good enough to miss elevated hopes.

For CAH, the near-term catalyst path is cleaner: a few quarters of stable margins and no further impairment surprises could mechanically expand valuation because the stock is still being treated as a low-multiple defensive rather than a growth-through-earnings compounder. The risk is that its growth narrative remains more concentrated and less forgiving; if earnings quality remains noisy, the market will keep assigning a discount despite attractive upside math. That creates a favorable setup for patient capital, but not for investors who need immediate relative performance.

The contrarian takeaway is that the crowd is likely over-anchored to UNH’s rebound and underestimating how quickly CAH can close the gap if its revised earnings power persists. In other words, UNH has already harvested a lot of the easy rerating, while CAH still has room for a rerating if management simply delivers and the market stops penalizing one-off noise.

Key Decisions for Investors

• Long CAH / short UNH in a 6-9 month relative-value pair; express the view that UNH’s rerating is largely complete while CAH still has multiple expansion runway. Use a 1:1 dollar-neutral structure and reassess if UNH outperforms by another 8-10% on a clean regulatory tape.
• Buy CAH on pullbacks over the next 2-4 weeks, targeting a 12-18 month horizon; risk/reward favors owning a low-beta defensive with upside to re-rating if EPS delivery remains intact. Add only if implied downside is limited below the recent post-earnings selloff zone.
• Avoid initiating fresh long UNH after the rebound unless there is a material drawdown or a new evidence point that lifts earnings visibility; current setup looks better for holders than for new money. If long already, consider trimming 20-30% into strength and keeping the rest as a core compounder.
• For options, consider CAH call spreads 6-12 months out to monetize upside without overpaying for volatility; this fits a thesis of gradual rerating rather than a sharp squeeze. Keep strikes modestly above spot to avoid overexposure to another earnings miss.
• Use UNH as a short-term momentum vehicle only if buying on post-news dips with a tight stop; the stock is vulnerable to headline gaps because expectations and positioning are now elevated. Favor tactical, not strategic, exposure.